ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4032-Chermside-The-Prince-Charles-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
18
trial(s) found.
NCT06960577
Curative
Phase 3
Recruiting
A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) (
D933RC00002
)
anti-PD-L1 monoclonal antibody
Bladder cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NA
NA
NCT06926868
Advanced
Phase 2 / Phase 3
Not yet recruiting
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable,or Metastatic Triple-negative Breast Cancer (TNBC)or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment (
CA244-0008
)
bispecific EGFR/ERBB3 antibody
Breast cancer
Triple-negative breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06764771
Advanced
Phase 1
Recruiting
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors (
CA234-0001
)
KRAS G12C inhibitor
Cancer
QLD
4032 - Chermside - The Prince Charles Hospital
NCT06690775
Advanced
Phase 2
Recruiting
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (
TORL123-002
)
Dexamethasone
Filgrastim
Pegfilgrastim
glucocorticoid
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06682988
Advanced
Phase 2
Recruiting
A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment (
IMGN853-0425
)
anti-FR-alpha antibody-drug conjugate
Fallopian tube cancer
QLD
4032 - Chermside - The Prince Charles Hospital
NCT06561386
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1% (
RELATIVITY1093
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4120 - Greenslopes - Greenslopes Private Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06312137
Curative
Phase 3
Recruiting
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (
TroFuse-019
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06297226
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (
QUINTESSENTIAL
)
autologous CAR-T cell therapy,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4032 - Chermside - The Prince Charles Hospital
NCT06120491
Advanced
Phase 3
Recruiting
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) (
EvoPAR-PR01
)
PARP1-selective inhibitor
placebo
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (TERMINATED)
2031 - Randwick - Prince of Wales Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5037 - Glandore - Ashford Cancer Centre
NCT06097728
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (
eVOLVE-Meso
)
anti-CTLA4 monoclonal antibody
anti-PD-1 monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
platinum-based antineoplastic agent
Pleural mesothelioma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05678673
Advanced
Phase 3
Recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (
STELLAR-304
)
KIT inhibitor,first generation
MET/VEGFR2/AXL/MER inhibitor
PDGFR inhibitor
VEGFR inhibitor
anti-PD-1 monoclonal antibody
Non-clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05128825
Advanced
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (
DENALI
/ ZN-c3-005 / GOG-3066)
WEE1 inhibitor
High-grade serous ovarian cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04938817
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98) (
3475-B98
)
anti-PD-1 monoclonal antibody
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital (COMPLETED)
WA
6009 - Nedlands - Hollywood Private Hospital
NCT03394365
Haem
Phase 3
Recruiting
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (
ALLELE
)
allogeneic T-cell immunotherapy,EBV-targeting
anti-CD20 monoclonal antibody
Solid tumour
NSW
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12624000582550
Curative
Phase 2
Recruiting
Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (
WOMBAT
) - ANZUP 2201
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12623000552684
Curative
Phase 2
Recruiting
OCEANiC
: A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by High-risk Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
EGFR inhibitor,third generation
EGFR-mutant non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12622000973718
Advanced
Phase 2
Recruiting
SHERLOCK
: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
anti-VEGF monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2170 - Liverpool - Liverpool Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT03906331
Advanced
Approved for marketing
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
RET-selective inhibitor
RET inhibitor
Selpercatinib
cancer therapy
cancer therapy,RET-targeting
Breast cancer
Colon adenocarcinoma
Medullary thyroid cancer
Non-small cell lung cancer
Pancreatic cancer
Papillary thyroid cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (16)
Not yet recruiting (1)
Approved for marketing (1)
Recruitment Country and State
QLD (17)
VIC (14)
NSW (11)
WA (11)
SA (9)
NZ (3)
TAS (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (7)
Phase 2 / Phase 3 (1)
Phase 3 (7)
Trial Type
Advanced (12)
Curative (4)
Haem (2)
Cancer Therapy Class
PD-1/PD-L1
39%
PD-1
33%
EGFR
17%
PD-L1
11%
KRAS
11%
KRAS G12C
11%
LAG3
11%
AR
11%
androgen axis
11%
CTLA4
11%
VEGF
11%
ERBB3
6%
FR-alpha
6%
Trop2
6%
GPRC5D
6%
CYP17A1
6%
PARP
6%
PARP1-selective
6%
AXL
6%
KIT
6%
MER
6%
MET
6%
PDGFR
6%
VEGFR
6%
VEGFR2
6%
WEE1
6%
ILT4
6%
CD20
6%
EBV
6%
LHRH
6%
oestrogen axis
6%
HRAS G12C
6%
NRAS G12C
6%
RET
6%
Facility
4032 - Chermside - The Prince Charles Hospital (18)
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (6)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (5)
6150 - Murdoch - Fiona Stanley Hospital (5)
3168 - Clayton - Monash Medical Centre (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
5112 - Elizabeth Vale - Lyell McEwin Hospital (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2170 - Liverpool - Liverpool Hospital (3)
2109 - North Ryde - Macquarie University Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
6009 - Nedlands - Linear Clinical Research (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2217 - Kogarah - St George Hospital (1)
NA
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
2031 - Randwick - Prince of Wales Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
5037 - Glandore - Ashford Cancer Centre (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3066 - Epping - Northern Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Urogenital cancer
Fallopian tube cancer
Breast cancer
Epithelial Ovarian Cancer
Gynaecological cancer
Ovarian cancer
Male genital cancers
Prostate cancer
Bladder cancer
Breast adenocarcinoma
Triple-negative breast cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Mesothelioma
Pleural mesothelioma
Kidney cancer
Non-clear cell renal cell carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Peritoneal cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
EGFR-mutant non-small cell lung cancer
Non-squamous non-small-cell lung cancer
Colon adenocarcinoma
Colorectal adenocarcinoma
Colorectal cancer
Differentiated thyroid carcinoma
Endocrine gland cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Medullary thyroid cancer
Pancreatic cancer
Pancreatobiliary cancer
Papillary thyroid cancer
Thyroid cancer
Upper gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy